Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Sanofi (0A2V) Share Price & Analysis

3 Followers

0A2V Stock Chart & Stats

$47.96$0.00(0.00%)
At close: 4:30 PM GMT
$40$42.5$45$47.5Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$47.55 - $48.13
52-Week Range
$39.19 - $52.65
Previous Close
$47.96
Volume
N/A
Average Volume (3M)
59.99K
Market Cap
$114.40B
Enterprise Value
$122.96B
Total Cash (Recent Filing)
$6.35B
Total Debt (Recent Filing)
$23.58B
Price to Earnings (P/E)
24.8
Beta
0.81
Next Earnings
Jan 28, 2027 (Est.)
EPS Estimate
0.96
Next Dividend Ex-Date
N/A
Dividend Yield
5.30%

Bulls Say, Bears Say

Bulls Say

Growth And Guidance

The upgraded 2026 outlook signals sustained commercial momentum across Sanofi’s portfolio rather than dependence on a single quarter. Low-teens sales growth and mid-teens business EPS growth should support reinvestment, strengthen operating leverage, and improve earnings durability over the next several quarters.

Dupixent Franchise

Dupixent’s scale, global patient adoption, and continued demand provide Sanofi with a powerful specialty-care earnings engine. Market leadership and expansion across major indications can support durable cash generation and help fund launches, pipeline investment, and portfolio renewal.

Balance Sheet Strength

Conservative leverage and a substantial equity base give Sanofi financial flexibility to invest through the development cycle. A solid balance sheet can support research, business development, and acquisitions while reducing the risk that financing constraints disrupt strategic priorities.

Bears Say

Pipeline Productivity

A pipeline that trails peers and recent program discontinuations create a durable replenishment challenge for a research-driven company. Sanofi must improve productivity and external sourcing to replace aging products, increasing execution demands and uncertainty around future growth.

Dupixent Exclusivity Risk

Dupixent is a major growth driver, so its eventual loss of exclusivity creates a material medium-term transition risk. Even with preparations underway, Sanofi must preserve earnings and cash flow while building replacement growth, which may constrain investment and margin expansion.

Portfolio And Pricing Headwinds

The planned exits simplify Sanofi’s portfolio but create a substantial revenue reset in 2027, while slightly negative pricing adds pressure to reported growth. The company therefore needs new launches and productivity gains to offset lost sales and protect its expansion profile.

Sanofi News

0A2V FAQ

What was Sanofi’s price range in the past 12 months?
Sanofi lowest share price was $39.19 and its highest was $52.65 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is $114.40B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s next earnings report is estimated for Jan 28, 2027 (not yet confirmed), which is in 77 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Oct 30, 2026. The company reported $1.981 earnings per share for the quarter, beating the consensus estimate of $1.555 by $0.426.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi does not currently pay dividends.
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 0.96.
How many shares outstanding does Sanofi have?
Sanofi has 2,415,546,900 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of $1.981 in its last earnings report, beating expectations of $1.555. Following the earnings report the stock price went up 4.713%.
Which hedge fund is a major shareholder of Sanofi?
Hedge funds hold Sanofi shares: the largest hedge-fund position in Sanofi is 1,988,720,547 shares, and hedge funds decreased their holdings by 1.7M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology